Topic: chronic kidney disease
Reata’s bardoxolone improved kidney function in a phase 3 trial of patients with a rare form of chronic kidney disease.
After ponying up more than $800 million on its deal with Reata Pharmaceuticals, AbbVie is calling it quits.
The filing follows data from Japanese phase 3 trials that assessed the oral HIF-PHI in chronic kidney disease patients.
The financing sets Sanifit up to take its lead drug through phase 3 while exploring its potential in other progressive vascular calcification disorders.
Shares in FibroGen plummeted as the wording of its number-free statement raised concerns about the safety of the kidney disease drug.
AstraZeneca tapped BenevolentAI to help bring artificial intelligence and machine learning to its drug discovery projects aimed at CKD and IPF.
The latest failure raised significant doubts about the future of vonapanitase, wiping 85% off Proteon’s stock price.
Though the Japanese data aren’t a perfect predictor for vadadustat’s global registrational studies, Piper Jaffray analysts called them “a nice proxy."
In rodent studies, exon skipping corrected a genetic error that's responsible for kidney disease linked to Joubert syndrome.
The phase 2 trial linked the Nrf2 activator to improvements in estimated glomerular filtration rate, a measure of kidney damage.